Targeted therapy prolongs life in patients with HER2-positive breast cancer

(Duke University Medical Center) Lapatinib plus trastuzumab are significantly better than lapatinib alone in extending the lives of breast cancer patients whose tumors are HER2-positive, according to Kimberly Blackwell, M.D., associate professor of medicine at Duke University Medical Center. Blackwell presented the findings today at the CTRC-AACR San Antonio Breast Cancer Symposium.

source : www.eurekalert.org

Related News:

• Mainstream media slants cancer articles toward unrealistically positive outcomes
• Dense Bones Linked To Raised Risk For Prostate Cancer
• New Surgery Without Incisions Shows Promise For Prostate Cancer Treatment
• Socially active environment can cause cancer tumors to shrink and even disappear
• Proposed Lowering Of PSA Threshold For Biopsy Could Result In Increased Overdiagnosis And Overtreatment Of Prostate Cancer, Study
• Association Of Body Mass Index With Prostate Cancer Biochemical Failure
• Starve A Cancer
• Circulating Aberrant Cells Increase As Non-Small Cell Lung Cancer Progresses
• Pool chemicals linked to disease
• Childhood Cancer Survivors May Have Trouble Having Kids

Details :
Submited at Friday, December 11th, 2009 at 7:00 pm on Cancer and Oncology by Gillan
Comment RSS 2.0 - leave a comment - trackback